Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MediciNova and the University of Colorado (CU) Boulder have disclosed a license agreement for the use of ibudilast (MN-166/AV411) for the treatment of post-traumatic brain injury (TBI).
Subscribe to our email newsletter
Ibudilast demonstrated significant efficacy in a model of post-TBI anxiety, one of the most common disorders caused by TBI.
A short course of systemic ibudilast administered over a month after concussion injury reversed post-TBI anxiety in rats for a three month measurement period following treatment.
Ibudilast is a selective inhibitor of macrophage-migration inhibitory factor (MIF) and certain phosphodiesterases with well-recognized activity as an attenuator of glial cell activation.
MediciNova is developing ibudilast (MN-166) for several neurological disorders.
MediciNova president and CEO said they are participating in research aimed at better understanding the traumatic brain injury disease process and in further exploring the potential for MN-166 as pharmacotherapy.